60 Degrees Pharmaceuticals, Inc.
SXTPAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | May 22, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | May 20, 2026 |
| Ascendiant Capital | maintain | Buy | Apr 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 27, 2026 |
| Ascendiant Capital | maintain | Buy | Nov 28, 2025 |
| Ascendiant Capital | maintain | Buy | Sep 3, 2025 |
| Ascendiant Capital | maintain | Buy | Jun 2, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 28, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Feb 25, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Jan 10, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Dec 23, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Dec 11, 2024 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.61| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.90 | $-0.73 | $207.9K | $185.0K |
| May 15, 2026 | $-1.28 | $-0.76 | $230.0K | $435.0K |
| Mar 26, 2026 | $-1.69 | $-2.28 | $310.0K | $320.0K |
| Nov 13, 2025 | $-2.64 | $-1.84 | $500.0K | $200.0K |
| Aug 12, 2025 | $-5.00 | $-4.96 | $305.0K | $320.0K |
| May 15, 2025 | $-6.24 | $-5.24 | $163.6K | $300.0K |
| Apr 7, 2025 | $-9.18 | $-4.77 | $230.0K | $250.0K |
| Nov 14, 2024 | $-18.60 | $-12.00 | $135.0K | $250.0K |
News
WASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi (USM) to assess the therapeutic potential of castanospermine—a naturally occurring iminosugar derived from the Australian Chestnut (Castan…
All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests Four of five completed patients (80%) were negative on highly sensitive post-treatment NAT testing Results reinforce favorable retreatment-free outcomes reported with tafenoquine–atovaquone regimens Two additional patients remain on treatment, bringing total enrollment to seven; study remains open pending potential discussions with FDA WASHINGTON, Oct…
Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation. Profitability This table compares Eyepoint Pharmaceuticals
After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded As of the same date, the Company had enrolled 30 patients Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment an…
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis ( NCT06207370 ) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.
Innoviva (NASDAQ: INVA - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Institutional and Insider Ownership 99.1% of Innoviva
60 Degrees Pharma (Nasdaq: SXTP) will present on demand at H.C. Wainwright beginning Sept. 11 and hold 1 x 1 investor meetings Sept. 14–16 in New York.
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand …